paclitaxel

Overview

Paclitaxel (Taxol) is a taxane that stabilizes microtubule polymers, preventing depolymerization and causing G2/M cell-cycle arrest and mitotic catastrophe. It is a first-line chemotherapy for multiple solid tumors including breast, ovarian, lung, and esophageal cancers. Paclitaxel also has radiosensitizing properties through G2/M accumulation.

Evidence in the corpus

  • In HER2+ OE19 esophageal cancer cells, T-DM1 was more potent than paclitaxel in head-to-head viability comparisons; paclitaxel was used as a clinical-drug comparator baseline alongside cisplatin, trastuzumab, lapatinib, and erlotinib PMID:27698471.
  • The paper positions paclitaxel as a conventional taxane radiosensitizer that acts via non-receptor-targeted microtubule stabilization, contrasting it with ADC-delivered anti-tubulin payloads (MMAE, mertansine) that restrict cytotoxicity to receptor-expressing tumours PMID:27698471.
  • 94% of the 489 HGSOC patients in the TCGA ovarian carcinoma cohort received a taxane (paclitaxel-class) alongside platinum-based chemotherapy PMID:21720365
  • TCGA endometrial cancer analysis (2013) identifies copy-number-high serous-like endometrial tumors (TP53-mutant, ~25% of high-grade endometrioid) as candidates for chemotherapy including paclitaxel, rather than standard adjuvant radiotherapy for endometrioid carcinoma PMID:23636398
  • Implicated in standard chemotherapy regimens for gastric adenocarcinoma (STAD); clonal heterogeneity analysis (HiC subtype, adjusted HR 4.69, P=0.0043) suggests combination targeting strategies are needed to address subclonal drivers PMID:25583476
  • Taxane chemotherapy; usable from second trimester in pregnant young-onset NSCLC patients as part of platinum-based combination regimens PMID:27346245
  • Taxane; listed among salvage/combination regimens in the clinical context of cisplatin-resistant GCT management PMID:27646943
  • TRMT10A loss in 22Rv1 and C4-2 mCRPC cells enhanced sensitivity to paclitaxel in addition to PARP inhibitors, consistent with impaired homologous recombination shifting double-strand break repair toward NHEJ/MMEJ PMID:28068672
  • Paclitaxel-containing regimens were used as chemotherapy in the 295-patient metastatic EGC cohort (MSK-IMPACT); HRD/LST scores did not predict platinum-based regimen PFS (HR=0.99, P=0.947) and MSI-H patients had inferior outcomes on cytotoxic therapy PMID:29122777

Resistance mechanisms

  • Not reported in corpus.

Cancer types (linked)

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:21720365

This page was processed by crosslinker on 2026-05-14. - PMID:23636398

This page was processed by crosslinker on 2026-05-14. - PMID:25583476

This page was processed by crosslinker on 2026-05-14. - PMID:27346245

This page was processed by wiki-cli on 2026-05-14. - PMID:27646943

This page was processed by wiki-cli on 2026-05-14. - PMID:28068672 — Yang et al., TRMT10A/USP10 axis in mCRPC; TRMT10A loss confers paclitaxel sensitivity in 22Rv1 and C4-2 cells consistent with impaired HR shifting DSB repair toward NHEJ/MMEJ.

*This page was processed by entity-page-writer on 2026-05-15. - PMID:29122777

This page was processed by wiki-cli on 2026-05-15.